- NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high.
- Shares are up more than 170% over the past 52 weeks.
- NEO maintains a 100% “Buy” technical opinion from Barchart.
- Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and recent profitability marking a compelling entry point.